28,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Although cerebral small vessel disease has been linked to stroke and dementia, due to limitations of current neuroimaging technology, direct in vivo visualization of changes in the cerebral small vessels (e.g., cerebral arteriolar narrowing, tortuous microvessels, blood-brain barrier damage, capillary microaneurysms) is difficult to achieve. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Type 2 diabetes (T2D) is a high risk factor for Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Melatonin is a hormone synthesized in the pineal gland from tryptophan. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The World Health Organization (WHO) burden of disease study identified dementia and hearing problems as leading causes of loss of quality of life in the industrial world. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Considerable attention has focused on the prevention of dementia in terms of non-genetic risk factors, including midlife obesity, especially visceral obesity associated with hyperglycemia, hypertension, and hypercholesterolemia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence of the cardiorenal metabolic syndrome (CRS) is increasing in parallel with obesity, type 2 diabetes mellitus, Alzheimer's disease, and other forms of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
White Matter Disease is increasingly being recognized as an important cause of cognitive decline and dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hypertension is a risk factor for stroke, ischemic white matter lesions, silent infarcts, general atherosclerosis, myocardial infarction and cardiovascular morbidity and mortality. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study explored effects of the metabolic syndrome (MetS) on language in aging. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Vaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer's disease will open a new concept in vaccination. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is growing evidence for the importance of cardiovascular risk factors in dementia development, including Alzheimer's disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is a cluster of risk factors for Type 2 diabetes and vascular disease that include high blood glucose, obesity, high blood pressure, increased blood triacylglycerols and insulin resistance. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The potential role of brain and cognitive reserve in traumatic brain injury (TBI) is reviewed. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Epidemiologic evidence suggests that individuals with higher IQ, education, occupational attainment, or participation in leisure activities have a reduced risk of developing Alzheimer disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Depression has an overall prevalence of 5-8%. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Depression and cognitive impairment are both common conditions in old age, and frequently occur together. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This brief report provides an introduction to the topic of cognitive functioning in late-life depression (LLD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article focuses on diagnostic and nosologic challenges intrinsic to geriatric depression, including characteristics interfering with symptom and syndrome ascertainment, the impact of medical and cognitive disorders, the usefulness of screening instruments, and barriers imposed by treatment settings. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Benefits of dietary moderation when on a Mediterranean diet type (MD) have been known for well over half a century. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Unlike Alzheimer's, vascular dementia can, in part, be prevented. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Vascular risk factors and cerebrovascular disease are common causes of dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic kidney disease, defined by a decreased glomerular filtration rate or albuminuria, is recognized as a major global health burden, mainly because it is an established risk factor for cardiovascular and cerebrovascular diseases. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The German psychiatrist Emil Kraepelin (1856 - 1926) is justly called father of modern psychiatry. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Glyphosate, the active ingredient in Roundup®, is the most popular herbicide used worldwide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Currently, diabetes mellitus (DM) is the most common metabolic disorder, which is manifested by hyperglycemia and leads to vascular and cognitive impairment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 3,795 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,980 records, built mostly from automated pulls of Europe PMC (62.8% of the library) and OpenAlex (17.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,038 records (3.6% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →